Sana Biotechnology Inc (SANA)
10.44
+0.66
(+6.75%)
USD |
NASDAQ |
May 03, 16:00
10.44
0.00 (0.00%)
After-Hours: 20:00
Sana Biotechnology Research and Development Expense (Quarterly): 69.84M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 69.84M |
| September 30, 2023 | -17.00M |
| June 30, 2023 | 99.72M |
| March 31, 2023 | 67.29M |
| December 31, 2022 | 58.47M |
| September 30, 2022 | 70.67M |
| June 30, 2022 | 54.61M |
| March 31, 2022 | 17.25M |
| December 31, 2021 | 98.60M |
| Date | Value |
|---|---|
| September 30, 2021 | 70.00M |
| June 30, 2021 | -31.03M |
| March 31, 2021 | 168.93M |
| December 31, 2020 | 104.12M |
| September 30, 2020 | 44.54M |
| June 30, 2020 | 81.90M |
| March 31, 2020 | 27.32M |
| December 31, 2019 | 39.27M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-31.03M
Minimum
Jun 2021
168.93M
Maximum
Mar 2021
60.26M
Average
67.29M
Median
Mar 2023
Research and Development Expense (Quarterly) Benchmarks
| Rocket Pharmaceuticals Inc | 41.74M |
| Solid Biosciences Inc | 15.45M |
| Dyne Therapeutics Inc | 58.84M |
| Taysha Gene Therapies Inc | 12.68M |
| Tenaya Therapeutics Inc | 22.86M |